Checkpoint Inhibitor denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Checkpoint Inhibitor — Duplicate Therapy

A "duplicate therapy" denial from UHC means the plan's system flagged that you are already approved for or receiving a drug in the same therapeutic class — typically another checkpoint inhibitor or immunotherapy agent. This denial arises most often in combination immunotherapy regimens (where two agents targeting different checkpoints are used together), or when a maintenance or continuation course is miscoded as a new prescription overlapping an active authorization.

Duplicate therapy denials in oncology are frequently incorrect as applied: combination checkpoint blockade is an FDA-approved, guideline-supported strategy for certain cancers, not redundant prescribing.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice; invoke expedited review (72-hour decision) if treatment delay poses a clinical risk.
• ACA §2719 external review: Available after exhausting or being deemed to have exhausted the internal process, within the ~4-month statutory window.
• ERISA §503 (employer-sponsored plans): Entitles you to the full clinical criteria applied and the claims data that triggered the duplicate flag.

## Documentation to Gather

1. Prescriber letter explaining the regimen: The oncologist should clearly describe each agent in the regimen, its distinct mechanism of action, the specific FDA-approved combination indication (or compendia support), and why both agents are required simultaneously. 2. FDA label and prescribing information: For each agent in the combination, the label will confirm the approved combination regimen and dosing schedule. 3. Claims and authorization records: Request UHC's claims data to identify exactly what existing authorization triggered the duplicate flag — this often reveals a coding error or an overlap between a prior authorization and a renewal. 4. NCCN guideline reference: The applicable NCCN guideline for the cancer type will list approved combination regimens; the oncologist should cite this to establish that the combination is a recognized standard, not duplication. 5. Diagnosis and staging documentation: Confirm the ICD-10 codes submitted accurately reflect the diagnosis and line of therapy.

## Criteria-Mapping Structure

Address the duplicate-therapy finding directly: identify each agent, its target (PD-1, PD-L1, CTLA-4, or other), and its distinct role in the regimen. Then map to the FDA-approved label and the applicable guideline to show that the combination is intentional, evidence-based, and approved — not duplicative. If the denial arose from a coding or authorization overlap, document the timeline of authorizations and administrations to show there is no actual duplication.